Table 4 Cox proportional hazard ratios for CYP2C19 genotypes, and the proposed tamoxifen activity groups according to CYP2D6 and CYP2C19 genotypes.
From: Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse
Univariable analysis | Multivariable analysis* | |||||
|---|---|---|---|---|---|---|
HR | 95% CI | p value | HR | 95% CI | p value | |
CYP2C19 genotypes | ||||||
CYP2C19*1/*1 | 1.000 | Reference | (0.923) | 1.000 | Reference | (0.977) |
CYP2C19*1/*2 | 0.863 | 0.116–6.434 | 0.874 | 0.778 | 0.098–6.156 | 0.812 |
CYP2C19*2/*2 | 0.657 | 0.090–4.807 | 0.679 | 0.525 | 0.068–4.039 | 0.536 |
CYP2C19*1/*17 | 0.817 | 0.490–1.716 | 0.787 | 0.883 | 0.460–1.693 | 0.707 |
CYP2C19*17/*17 | 0.795 | 0.191–3.314 | 0.753 | 0.643 | 0.146–2.839 | 0.560 |
CYP2C19*2/*17 | 1.066 | 0.378–3.012 | 0.904 | 1.089 | 0.360–3.097 | 0.921 |
CYP2C19*2 | ||||||
*1/*1 and *1/*2 | 1.000 | Reference | 1.000 | Reference | ||
*2/*2 | 0.755 | 0.104–5.471 | 0.781 | 0.678 | 0.090–5.131 | 0.707 |
CYP2C19*17 | ||||||
*1/*1 and *1/*17 | 1.000 | Reference | 1.000 | Reference | ||
*17/*17 | 1.896 | 0.684–5.259 | 0.219 | 1.837 | 0.621–5.441 | 0.272 |
Activity groups according to proposed CYP2D6 and CYP2C19 genotypes | ||||||
Low activity group | 1.000 | Reference | (0.174) | 1.000 | Reference | (0.235) |
Intermediate activity group | 1.624 | 0.582–4.531 | 0.355 | 1.598 | 0.561–4.550 | 0.380 |
High activity group | 0.725 | 0.194–2.704 | 0.632 | 0.759 | 0.199–2.902 | 0.687 |
